Omeros CorpNASDAQ:OMER
- LAST PRICE3.8800
- TODAY'S CHANGE (%)0.0300 (0.7792%)
- Bid / Lots3.8000/ 3
- Ask / Lots4.0000/ 2
- Open / Previous Close3.8600 / 3.8500
- Day Range
- 52 Week Range
- Volume66,864
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | OMER |
|---|---|---|
| 09:32 ET | 1380 | 3.86 |
| 09:41 ET | 400 | 3.875 |
| 09:43 ET | 546 | 3.88 |
| 09:45 ET | 100 | 3.885 |
| 09:50 ET | 800 | 3.895 |
| 09:54 ET | 200 | 3.89 |
| 09:57 ET | 400 | 3.875 |
| 10:01 ET | 1000 | 3.875 |
| 10:12 ET | 500 | 3.895 |
| 10:15 ET | 898 | 3.92 |
| 10:17 ET | 154 | 3.928 |
| 10:19 ET | 100 | 3.93 |
| 10:24 ET | 929 | 3.93 |
| 10:28 ET | 300 | 3.94 |
| 10:30 ET | 200 | 3.955 |
| 10:32 ET | 519 | 3.953 |
| 10:37 ET | 468 | 3.96 |
| 10:39 ET | 300 | 3.94 |
| 10:44 ET | 225 | 3.935 |
| 10:50 ET | 3043 | 3.915 |
| 10:51 ET | 224 | 3.915 |
| 10:53 ET | 400 | 3.915 |
| 10:55 ET | 600 | 3.9 |
| 11:00 ET | 200 | 3.885 |
| 11:02 ET | 1312 | 3.88 |
| 11:04 ET | 150 | 3.88 |
| 11:06 ET | 100 | 3.89 |
| 11:08 ET | 200 | 3.87 |
| 11:09 ET | 196 | 3.87 |
| 11:11 ET | 100 | 3.87 |
| 11:13 ET | 350 | 3.88 |
| 11:15 ET | 224 | 3.88 |
| 11:20 ET | 400 | 3.85 |
| 11:22 ET | 200 | 3.865 |
| 11:24 ET | 225 | 3.86 |
| 11:26 ET | 100 | 3.86 |
| 11:29 ET | 327 | 3.84 |
| 11:31 ET | 2380 | 3.8477 |
| 11:33 ET | 100 | 3.83 |
| 11:36 ET | 500 | 3.84 |
| 11:38 ET | 4003 | 3.85 |
| 11:40 ET | 100 | 3.86 |
| 11:42 ET | 200 | 3.85 |
| 11:45 ET | 100 | 3.85 |
| 11:47 ET | 200 | 3.85 |
| 11:49 ET | 900 | 3.87 |
| 11:51 ET | 1543 | 3.87 |
| 11:56 ET | 229 | 3.88 |
| 12:00 ET | 100 | 3.88 |
| 12:02 ET | 1125 | 3.86 |
| 12:03 ET | 902 | 3.86 |
| 12:07 ET | 100 | 3.865 |
| 12:09 ET | 728 | 3.88 |
| 12:12 ET | 200 | 3.9 |
| 12:14 ET | 100 | 3.9 |
| 12:16 ET | 224 | 3.895 |
| 12:18 ET | 762 | 3.88 |
| 12:20 ET | 244 | 3.89 |
| 12:21 ET | 200 | 3.89 |
| 12:23 ET | 189 | 3.89 |
| 12:25 ET | 227 | 3.89 |
| 12:30 ET | 1379 | 3.88 |
| 12:34 ET | 526 | 3.88 |
| 12:36 ET | 647 | 3.885 |
| 12:38 ET | 477 | 3.88 |
| 12:39 ET | 334 | 3.88 |
| 12:43 ET | 233 | 3.88 |
| 12:45 ET | 200 | 3.875 |
| 12:48 ET | 930 | 3.88 |
| 12:50 ET | 231 | 3.88 |
| 12:54 ET | 597 | 3.88 |
| 12:56 ET | 419 | 3.89 |
| 12:57 ET | 1595 | 3.87 |
| 12:59 ET | 2016 | 3.88 |
Jun 4, 2024
Omeros Announces Webcast Details for Annual Meeting of Shareholders, from 9:00AM ET on Tuesday Jun 04, 2024 by Dow Jones
9:00AM ET on Tuesday Jun 04, 2024 by Dow Jones
Jun 3, 2024
DJ Omeros Shares Rise on Balance Sheet Strengthening, from 11:33AM ET on Monday Jun 03, 2024 by Dow Jones
11:33AM ET on Monday Jun 03, 2024 by Dow JonesOmeros Corporation Further Strengthens its Balance Sheet through Series of Financing Transactions Extending Maturity on a Majority of its Outstanding Debt into 2028, from 9:00AM ET on Monday Jun 03, 2024 by Dow Jones
9:00AM ET on Monday Jun 03, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Omeros Corp | 223.1M | -1.3x | --- |
Vicapsys Life Sciences Inc | 225.5M | -214.8x | --- |
Greenwich Lifesciences Inc | 226.4M | -23.2x | --- |
ESSA Pharma Inc | 218.7M | -7.6x | --- |
Monte Rosa Therapeutics Inc | 218.4M | -1.5x | --- |
Zura Bio Ltd | 218.4M | -2.1x | --- |
Company Information
Omeros Corporation is a biopharmaceutical company. The Company is focused on discovering, developing and commercializing small-molecule and protein therapeutics for large-market and orphan indications targeting immunologic disorders, including complement-mediated diseases, cancers, and addictive and compulsive disorders. Its lead MASP-2 inhibitor, narsoplimab, targets the lectin pathway of complement and is the subject of a biologics license application pending before FDA for the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy. Its long-acting MASP-2 inhibitor, OMS1029, is in a phase I multi-ascending-dose clinical trial. OMS906, its inhibitor of MASP-3, the key activator of the alternative pathway of complement, is advancing in clinical programs for paroxysmal nocturnal hemoglobinuria and complement 3 glomerulopathy. The Company’s lead phosphodiesterase 7 inhibitor OMS527 is in clinical development for the treatment of cocaine use disorders.
Contact Information
- Headquarters
- 201 Elliott Avenue WestSEATTLE, WA, United States 98119
- Phone
- 206-676-5000
- Fax
- 206-676-5005
Executives
- Chairman of the Board, President, Chief Executive Officer
- Gregory Demopulos
- Chief Accounting Officer, Vice President - Finance, Treasurer
- David Borges
- Chief Accounting Officer, Vice President - Finance
- Michael Jacobsen
- Vice President - Science, Chief Scientific Officer
- George Gaitanaris
- Vice President, General Counsel, Secretary
- Peter Cancelmo
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $223.1M |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 57.9M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.46 |
EPS | $-2.90 |
Book Value | $-0.41 |
P/E Ratio | -1.3x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
